Redmile Group LLC cut its holdings in Axonics Modulation Technologies Inc (NASDAQ:AXNX) by 0.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 598,600 shares of the company’s stock after selling 1,400 shares during the quarter. Redmile Group LLC’s holdings in Axonics Modulation Technologies were worth $14,336,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of AXNX. Citigroup Inc. purchased a new position in shares of Axonics Modulation Technologies during the fourth quarter valued at approximately $28,000. Barclays PLC purchased a new position in Axonics Modulation Technologies in the 4th quarter worth approximately $31,000. American International Group Inc. purchased a new position in Axonics Modulation Technologies in the 4th quarter worth approximately $69,000. Deutsche Bank AG purchased a new position in Axonics Modulation Technologies in the 4th quarter worth approximately $137,000. Finally, Westfield Capital Management Co. LP purchased a new position in Axonics Modulation Technologies in the 1st quarter worth approximately $261,000. Institutional investors and hedge funds own 29.27% of the company’s stock.

Shares of NASDAQ AXNX opened at $34.60 on Monday. Axonics Modulation Technologies Inc has a twelve month low of $11.95 and a twelve month high of $35.28. The company has a market capitalization of $978.00 million and a P/E ratio of -7.46. The company has a quick ratio of 22.07, a current ratio of 22.83 and a debt-to-equity ratio of 0.16.

Axonics Modulation Technologies (NASDAQ:AXNX) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.07). The company had revenue of $1.08 million for the quarter, compared to the consensus estimate of $0.53 million. Sell-side analysts expect that Axonics Modulation Technologies Inc will post -2.03 earnings per share for the current fiscal year.

In other Axonics Modulation Technologies news, COO Rinda Sama sold 13,345 shares of Axonics Modulation Technologies stock in a transaction that occurred on Thursday, May 9th. The shares were sold at an average price of $28.03, for a total value of $374,060.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

A number of equities analysts recently weighed in on the stock. Bank of America boosted their price objective on shares of Axonics Modulation Technologies from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday. Zacks Investment Research lowered shares of Axonics Modulation Technologies from a “hold” rating to a “sell” rating in a report on Monday, May 20th. Finally, SunTrust Banks boosted their price objective on shares of Axonics Modulation Technologies to $33.00 and gave the stock a “buy” rating in a report on Friday, May 10th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Axonics Modulation Technologies presently has an average rating of “Buy” and an average price target of $25.78.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/axonics-modulation-technologies-inc-nasdaqaxnx-shares-sold-by-redmile-group-llc/3044119.html.

Axonics Modulation Technologies Profile

Axonics Modulation Technologies, Inc, a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, including urinary urgency incontinence and urinary urgency frequency, fecal incontinence, and urinary retention.

See Also: Street Name

Want to see what other hedge funds are holding AXNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axonics Modulation Technologies Inc (NASDAQ:AXNX).

Institutional Ownership by Quarter for Axonics Modulation Technologies (NASDAQ:AXNX)

Receive News & Ratings for Axonics Modulation Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics Modulation Technologies and related companies with MarketBeat.com's FREE daily email newsletter.